Pieris Pharmaceuticals Inc (PIRS)

Sector:
HEALTH CARE
Industry:
PHARMACEUTICALS
SIC:
PHARMACEUTICAL PREPARATIONS
CEO:
Stephen S. Yoder
Employees:
140
255 STATE STREET, 9TH FLOOR, BOSTON, MA 02109
857-246-8998

Pieris Pharmaceuticals, Inc. develops anticalin proteins that are low molecular-weight therapeutic proteins derived from lipocalins. Its lead respiratory Anticalin-based drug candidate includes PRS-060/AZD1402, a drug candidate that is in Phase II clinical trial targeting IL-4Ra for the treatment of asthma and other inflammatory diseases. The company also develops a 4-1BB/ HER2 bispecific program addressing undisclosed targets for immuno-oncology diseases.

Data derived from most recent annual or quarterly report
Market Cap 19.474 Million Shares Outstanding98.852 Million Avg 30-day Volume 421.616 Thousand
P/E Ratio0.0 Dividend Yield0.0 EPS-0.11
Price to Revenue0.4377 Debt to Equity0.0 EBITDA-34.482 Million
Price to Book Value0.3589 Operating Margin-111.8288 Enterprise Value-40.34 Million
Current Ratio1.934 EPS Growth0 Quick Ratio1.624
1 Yr BETA 1.194 52-week High/Low 1.97 / 0.16 Profit Margin-81.4437
Operating Cash Flow Growth27.5118 Free Cash Flow to Firm (FCFF) TTM -48.189 Million Free Cash Flow to Equity (FCFE) TTM-26.133 Million
Altman Z-Score-5.1867
View SEC Filings from PIRS instead.

View recent insider trading info

Pieris Pharmaceuticals Inc YCharts
Yahoo! Finance finviz
SEC Web Site SEC DEF 14A Filings

Funds Holding PIRS (via 13F filings)

Refresh Download CSV Download Excel (.xlsx) Download TSV
Filter by:
Click for Additional Filters
to
to
to
Refresh
*Shares are split adjusted
*Please note that if a filer hasn't submitted a 13F filing for a quarter then the filer's shares will be listed as "Sold All"

Mutual Funds Holding PIRS

Download CSV

Active Schedule 13D and 13G filings

Please sign in first

Recent Filings

Financial Reporting

Ownership

  • 4: filed on 2023-06-23 by BARBIER ANN
  • 4: filed on 2023-06-23 by SAID MAYA R.
  • 4: filed on 2023-02-28 by BURES THOMAS
  • 4: filed on 2023-02-28 by KAUFMANN HITTO
  • 4: filed on 2023-02-28 by MOUSA AHMED
  • 4: filed on 2023-02-28 by OLWILL SHANE
  • 4: filed on 2023-02-28 by YODER STEPHEN S.
  • 4: filed on 2022-06-24 by BARBIER ANN
  • 4: filed on 2022-06-24 by SAID MAYA R.
  • 4: filed on 2022-06-24 by GERAGHTY JAMES A

    • Events (8k)

  • 8-K/A: filed on 2023-08-31:
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-18:
    Item 1.02: Termination of a Material Definitive Agreement
    Item 2.02: Results of Operations and Financial Condition
    Item 2.05: Cost Associated with Exit or Disposal Activities
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-07-13:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-26:
    Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers
    Item 5.07: Submission of Matters to a Vote of Security Holders
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-21:
    Item 2.02: Results of Operations and Financial Condition
    Item 8.01: Other Events
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-06-08:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-05-19:
    Item 3.01: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing
  • 8-K: filed on 2023-05-10:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-03-29:
    Item 2.02: Results of Operations and Financial Condition
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits
  • 8-K: filed on 2023-01-10:
    Item 7.01: Regulation FD Disclosure
    Item 9.01: Financial Statements and Exhibits

    • Proposed Sales (Form 144)

    Proxy

    Prospectus

    All

    Open Market Buys/Sells Last 60 Days

    Open Market Buys (P)

    none

    Open Market Sells (S)

    none

    Exercise Derivative Conversion (M)

    none

    Current/Former Insiders

    Insider Name Type Last Reported Shares Held Last Reported Date Filings in past year

    GERAGHTY JAMES A

    • Director
    		 0 2023-06-21 1

    KIRITSY CHRISTOPHER P

    • Director
    		 0 2023-06-21 2

    SHERMAN MATTHEW L

    • Director
    		 0 2023-06-21 1

    KIENER PETER A

    • Director
    		 0 2023-06-21 1

    RICHMAN MICHAEL

    • Director
    		 0 2023-06-21 1

    BARBIER ANN

    • Director
    		 0 2023-06-21 1

    SAID MAYA R.

    • Director
    		 0 2023-06-21 1

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BVF I GP LLC

    BIOTECHNOLOGY VALUE FUND II LP

    BVF II GP LLC

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF GP HOLDINGS LLC

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		20,333,557 2023-05-11 1

    YODER STEPHEN S. CHIEF EXECUTIVE OFFICER

    • Officer
    • Director
    		 0 2023-02-24 1

    BURES THOMAS CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2023-02-24 1

    KAUFMANN HITTO CHIEF SCIENTIFIC OFFICER

    • Officer
    		 0 2023-02-24 1

    OLWILL SHANE CHIEF DEVELOPMENT OFFICER

    • Officer
    		 0 2023-02-24 1

    MOUSA AHMED CHIEF BUSINESS OFFICER

    • Officer
    		 0 2023-02-24 1

    DEMUTH TIM CHIEF MEDICAL OFFICER

    • Officer
    		 6,000 2022-05-13 0

    AQUILO CAPITAL MANAGEMENT, LLC

    • 10% Owner
    		 No longer subject to file 2020-07-21 0

    BIZZARI JEAN-PIERRE

    • Director
    		 20,000 2020-01-25 0

    BVF PARTNERS L P/IL

    BIOTECHNOLOGY VALUE FUND L P

    BIOTECHNOLOGY VALUE FUND II LP

    BIOTECHNOLOGY VALUE TRADING FUND OS LP

    BVF PARTNERS OS LTD.

    BVF INC/IL

    LAMPERT MARK N

    • 10% Owner
    • SEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSESSEE EXPLANATION OF RESPONSES
    		No longer subject to file 2019-09-06 0

    MATIS LOUIS CHIEF DEVELOPMENT OFFICER

    • Officer
    		 106,500 2019-02-26 0

    REINE ALLAN CHIEF FINANCIAL OFFICER

    • Officer
    		 227,500 2019-02-26 0

    PRELACK STEVEN

    • Director
    		 20,000 2019-01-25 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP III LLC

    • 10% Owner
    • SEE REMARKSSEE REMARKS
    		 4,550,000 2018-04-30 0

    ADAMS JULIAN

    • Director
    		 20,000 2018-01-25 0

    ORBIMED ADVISORS LLC

    ORBIMED CAPITAL GP III LLC

    ISALY SAMUEL D

    • 10% Owner
    		 5,550,000 2018-01-03 0

    KHUONG CHAU QUANG

    • Director
    • 10% Owner
    		 7,265,735 2017-10-25 0

    THIBAULT LANCE E ACTING CHIEF FINANCIAL OFFICER

    • Officer
    		 0 2017-02-02 0

    KNOPF CLAUDE CHIEF BUSINESS OFFICER

    • Officer
    		 0 2016-11-28 0

    DEPTULA-HICKS DARLENE M SVP, CHIEF FINANCIAL OFFICER

    • Officer
    		 5,000 2016-06-13 0

    TAKKE CHRISTINA

    • Director
    		 0 2015-06-29 0

    Insider Transactions Last 60 Days

    Reporting Owners Filing Date Trans Date Trans Code Shares Share Price Acquired
    Disposed    		 Shares Owned after D/I 10b5 Perf 1d* Perf 5d* Perf 1m* Max Gain Max Gain Days Max Loss Max Loss Days
    No current insider transactions

    * -

    Transaction Code Definitions
    Code Definition
    A Grant, award or other acquisition pursuant to Rule 16b-3(d)
    C Conversion of derivative security
    D Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e)
    E Expiration of short derivative position
    F Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3
    G Bona fide gift
    H Expiration (or cancellation) of long derivative position with value received
    I Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities
    J Other acquisition or disposition
    L Small acquisition under Rule 16a-6
    M Exercise or conversion of derivative security exempted pursuant to Rule 16b-3
    O Exercise of out-of-the-money derivative security
    P Open market or private purchase of non-derivative or derivative security
    S Open market or private sale of non-derivative or derivative security
    U Disposition pursuant to a tender of shares in a change of control transaction
    W Acquisition or disposition by will or the laws of descent and distribution
    X Exercise of in-the-money or at-the-money derivative security
    Z Deposit into or withdrawal from voting trust

    IBR Securities Loan Availability

    Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers

    Security Date/Time Rebate Rate Fee Rate Shares Available
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 22:15:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 21:45:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 21:15:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 20:45:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 20:15:07 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 19:45:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 19:15:03 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 18:45:03 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 18:15:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 17:45:03 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 17:15:03 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 16:45:05 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 16:15:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 15:45:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 15:15:04 UTC -5.8501 11.1701 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 14:45:04 UTC -4.159 9.479 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 14:15:03 UTC -4.159 9.479 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 13:45:03 UTC -7.02 12.34 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 13:15:04 UTC -7.02 12.34 3400000
    PIERIS PHARMACEUTICALS INC PIRS 2023-12-08 12:45:05 UTC -7.02 12.34 3200000

    Current Active Short Positions

    Holder Issuer Net Short Position Position Date Origin

    No recent transactions

    *** To see all congressional transactions (since 2022) for this stock, please use the congressional transaction search page***

    WhaleWisdom Logo

    Elevate your investments